G. Martinengo

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.

M. Rizzo, G. Recondo, R. Kowalyszyn, 2020, Clinical lung cancer.

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

C. Dooms, M. Tsuboi, H. Wakelee, 2023, The New England journal of medicine.